Evaluation of Patients With Known or Suspected Heart Disease

Heart Failure Clinical Trial

Official title:

Evaluation of Patients With Known or Suspected Heart Disease (Screening Protocol)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00001313
• Other study ID #: 920189
• Secondary ID: 92-H-0189
• Status: Completed
• Phase: N/A
• First received: November 3, 1999
• Last updated: June 30, 2017
• Start date: May 10, 1992
• Est. completion date: January 6, 2009

Study information

• Verified date: January 6, 2009
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In this study researchers will admit and evaluate patients with known or suspected heart disease referred to the Cardiology Branch of the National Heart, Lung, and Blood Institute (NHLBI).

Patients participating in this study will undergo a general medical evaluation, including blood tests, urine, examination, chest x-ray and electrocardiogram (EKG). In addition, patients may be asked to have an echocardiogram (ultrasound scan of the heart) and to perform an exercise stress test.

These tests are designed to assess the types and causes of patient's heart diseases and to determine if they can participate in other, specific research studies.

Description:

The principal mission of the NIH is the conduct of research that elucidates biological mechanisms, pathogenesis, and treatment of disease. Patients with known or suspected cardiovascular diseases are referred to NHLBI cardiologists for consideration of participation in clinical research protocols. However, eligibility for participation is often uncertain from referral information or even after an outpatient evaluation. The purpose of this protocol is to permit inpatient evaluation of patients for whom participation in clinical research protocols is under consideration in order to determine protocol eligibility by means of conventional laboratory and cardiovascular testing.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: January 6, 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

• INCLUSION CRITERIA:

The following is a representative list of the types of patient presentations and potential diagnoses eligible for this protocol:

1. Coronary artery disease with angina or inducible myocardial ischemia as determined by noninvasive testing.

2. Cardiomyopathies including congestive phenotypes.

3. Peripheral artery disease with intermittent claudication or limb-threatening ischemia.

4. Renovascular disease with uncontrolled hypertension, intermittent pulmonary edema, or evidence of ischemic nephropathy.

5. Upper extremity peripheral artery disease.

6. Diabetes with heart failure.

7. Pulmonary hypertension.

EXCLUSION CRITERIA:

Pregnancy, for those patients who require catheterization-based diagnostics.

Inability to provide informed consent.

Related Conditions & MeSH terms

• Cardiomyopathies
• Cardiomyopathy, Dilated
• Coronary Artery Disease
• Coronary Disease
• Diabetes and Heart Failure
• Dilated Cardiomyopathy
• Heart Diseases
• Heart Failure
• Hypertension, Pulmonary
• Peripheral Arterial Disease
• Peripheral Artery Disease
• Pulmonary Hypertension
• Renal Artery Obstruction
• Renal Artery Stenosis

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center, 9000 Rockville Pike	Bethesda	Maryland
United States	Suburban Hospital	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States,